Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Trial Profile

Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANAVEX-2-73/donepezil (Primary) ; Blarcamesine (Primary) ; Blarcamesine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Anavex Life Sciences
  • Most Recent Events

    • 26 Oct 2018 According to an Anavex Life Sciences media release, 3 year longitudinal data from the study were presented at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
    • 26 Oct 2018 3 year longitudinal data from the study presented in an Anavex Life Sciences media release.
    • 19 Sep 2018 According to an Ariana Pharmaceuticals media release, data from this and extension portion of the trial will be presented at CTAD in October 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top